Potential Drug Target For Future Malaria And Anti-Cancer Treatments
5/31/2011
Researchers from the Walter and Eliza Hall Institute have overturned conventional wisdom on how cell movement across all species is controlled, solving the structure of a protein that cuts power to the cell 'motor'. The protein could be a potential drug target for future malaria and anti-cancer treatments...
Researchers Bringing Failing Hearts Back From The Brink
5/31/2011
A promising cancer treatment drug can restore function of a heart en route to failure from high blood pressure, researchers at UT Southwestern Medical Center have found. The drug, a type of histone deacetylase (HDAC) inhibitor being evaluated in numerous ongoing clinical trials, has been shown to reverse the harmful effects of autophagy in heart muscle cells of mice...
New Breast Screening Guidelines Leave 80% Of Women Uneasy
5/31/2011
Over four-fifths of women feel uneasy about being told that routine breast cancer screening for the under 50s is not obligatory. Guidelines issued by the U.S. Preventive Services Task Force (USPSTF) in 2009 upped the minimum age from which women should routinely be screened for breast cancer from 40 to 50 years, and also said that screening should occur every two years up to the age of 74...
A study titled "Abiraterone and Increased Survival in Metastatic Prostate Cancer," published in the May 26 issue of NEJM, found that patients with metastatic castration-resistant prostate cancer who have received prior chemotherapy containing docetaxel showed a significant improvement in overall survival when treated with ZYTIGA™ (abiraterone acetate) plus prednisone comp...
Veridex Launches CELLTRACKS® Circulating Melanoma Cell Kit For Research Use
5/31/2011
Veridex, LLC announced the launch of the CELLTRACKS® Circulating Melanoma Cell (CMC) kit, providing research scientists with a fast, convenient and reliable way to capture CMCs for research studies...
Signal Genetics, the parent company of Myeloma Health LLC and Respira Health LLC, a privately held predictive genetic testing company focused on oncology, announced a new agreement under which NeoGenomics Laboratories will offer Signal Genetics' new gene expression profile test for Multiple Myeloma (MyPRS™) to pathologists and hospital-based hematologists/oncologists nationwide...
Augurex Life Sciences Corp. reported that in London at the European League Against Rheumatism (EULAR) Conference, leading arthritis researchers presented important data on Augurex's rheumatoid arthritis (RA) biomarker blood test and novel drug target...
Risk Of Blood Clots In Veins Hereditary
5/31/2011
Venous thromboembolism (VTE) is the third most common type of cardiovascular disease after coronary heart disease and stroke...
New Breast Screening Guidelines Leave 80% Of Women Uneasy
5/30/2011
Over four-fifths of women feel uneasy about being told that routine breast cancer screening for the under 50s is not obligatory. Guidelines issued by the U.S. Preventive Services Task Force (USPSTF) in 2009 upped the minimum age from which women should routinely be screened for breast cancer from 40 to 50 years, and also said that screening should occur every two years up to the age of 74...
Clavis Pharma ASA (OSE: CLAVIS), the Norwegian cancer drug development company, is pleased to announce that it has been awarded a grant from The Research Council of Norway of up to NOK 14 mill (USD 2...